Nome Químico: 2-(2-(2-(2-acetylhydrazinyl)-2-oxoacetamido)propan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
Sorrisos: CC(C)(C(N1C)=NC(C(NCC2=CC=C(F)C=C2)=O)=C(O)C1=O)NC(C(NNC(C)=O)=O)=O
Inchi: InChI=1S/C13H15ClN2O2/c1-16(15-18)13(9-5-4-8-12(13)17)10-6-2-3-7-11(10)14/h2-3,6-7H,4-5,8-9H2,1H3/t13-/m0/s1
Development and validation of stability indicating RP-HPLC assay method of raltegravir in tablet dosage forms
By Shirisha, V.; Sairaju, B.; Illendula, Santhosh; Dutt, K. Rajeswar
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(10), 668-692
Stability indicating reverse-phase high performance liquid chromatography method for the determination of raltegravir in bulk and pharmaceutical formulation
By Annapurna, Mukthinuthalapati Mathrusri; Teja, Gunnam Ravi; Hemchand, S.; Babu, R. Ravi Chandra
From International Journal of Green Pharmacy (2018), 12(1Suppl.), S177-S180
Development and validation of RP-HPLC method for determination of raltegravir and its impurities in bulk drug and dosage forms
By Balaji, M.; AppaRao, K. M. Ch.; Ramakrishna, K.; Srinivasarao, V.
From Pharma Science Monitor (2014), 5(3Suppl.1), 187-196, 10 pp.